{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T23:08:30Z","timestamp":1754262510336,"version":"3.37.3"},"reference-count":33,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T00:00:00Z","timestamp":1520726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573498","81703610"],"award-info":[{"award-number":["81573498","81703610"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2017M612599"],"award-info":[{"award-number":["2017M612599"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2018,7]]},"abstract":"Summary<\/jats:title>Etanercept (ETN<\/jats:styled-content>) is a widely used anti\u2010tumour necrosis factor\u2010\u03b1 (TNF<\/jats:styled-content>\u2010\u03b1) agent, which relieves the symptoms of ankylosing spondylitis (AS<\/jats:styled-content>) by binding to TNF<\/jats:styled-content>\u2010\u03b1 to inhibit its inflammation effects. In this study, the effect of TNF<\/jats:styled-content>\u2010\u03b1 level on ETN<\/jats:styled-content> clearance (CL<\/jats:styled-content>) was investigated, and the TNF<\/jats:styled-content>\u2010\u03b1 concentration was initially set as a correction factor for allometric scaling to improve the predictions of individual ETN CL<\/jats:styled-content>s. Individual ETN CL<\/jats:styled-content>s and TNF<\/jats:styled-content>\u2010\u03b1 concentrations in healthy volunteers and patients with AS<\/jats:styled-content> were determined by performing ETN<\/jats:styled-content> pharmacokinetic studies in the two cohorts. Accordingly, individual ETN CL<\/jats:styled-content>s in both healthy volunteers and patients with AS<\/jats:styled-content> were predicted from data of two animal species using different methods, including simple allometric scaling, scaling with a correction factor of maximum life span potential or brain weight, and scaling with a correction factor of the TNF<\/jats:styled-content>\u2010\u03b1 concentration. The accuracies of such predictions were evaluated by the percentage errors. Consequently, increased TNF<\/jats:styled-content>\u2010\u03b1 concentration was shown to improve ETN CL<\/jats:styled-content>, by comparing both ETN CL<\/jats:styled-content>s and TNF<\/jats:styled-content>\u2010\u03b1 concentrations between healthy volunteers and patients with AS<\/jats:styled-content>. More importantly, better predictions of individual ETN CL<\/jats:styled-content>s were achieved in patients with AS<\/jats:styled-content> using allometric scaling with TNF<\/jats:styled-content>\u2010\u03b1 concentration as the correction factor. In conclusion, in vivo levels of TNF<\/jats:styled-content>\u2010\u03b1 can affect ETN CL<\/jats:styled-content>, and allometric scaling corrected with the TNF<\/jats:styled-content>\u2010\u03b1 concentration can be used to estimate the individual CL<\/jats:styled-content>s of anti\u2010TNF<\/jats:styled-content>\u2010\u03b1 monoclonal antibodies based on preclinical data.<\/jats:p>","DOI":"10.1111\/1440-1681.12924","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T12:06:47Z","timestamp":1518523607000},"page":"643-651","source":"Crossref","is-referenced-by-count":9,"title":["TNF<\/scp>\u2010\u03b1 level affects etanercept clearance: TNF<\/scp>\u2010\u03b1 concentration as a new correction factor of allometric scaling to predict individual etanercept clearances in patients with ankylosing spondylitis"],"prefix":"10.1111","volume":"45","author":[{"given":"Yuwei","family":"Deng","sequence":"first","affiliation":[{"name":"Research Institute of Drug Metabolism and Pharmacokinetics School of Pharmaceutical Sciences Central South University Changsha Hunan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Shenzhen People's Hospital Shenzhen Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Qiang","sequence":"additional","affiliation":[{"name":"Research Institute of Drug Metabolism and Pharmacokinetics School of Pharmaceutical Sciences Central South University Changsha Hunan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeneng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Research Institute of Drug Metabolism and Pharmacokinetics School of Pharmaceutical Sciences Central South University Changsha Hunan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7901-8419","authenticated-orcid":false,"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Research Institute of Drug Metabolism and Pharmacokinetics School of Pharmaceutical Sciences Central South University Changsha Hunan China"},{"name":"School of Life Sciences Central South University Changsha Hunan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology The Second Hospital of Shanxi Medical University Taiyuan Shanxi China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.12.985"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.01.003"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.3.329"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205862"},{"key":"e_1_2_7_8_1","first-page":"1719","article-title":"Long\u2010term safety and efficacy of infliximab for the treatment of ankylosing spondylitis","volume":"11","author":"Elalouf O","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.4990"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1149-4"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11325"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1500523"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.708"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01062336"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498259609052491"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21682"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-669"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8542-z"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0283-5"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-11-RG-011"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-015-0270-9"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018943613122"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006286435"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19126"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2001.01279.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014414520282"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.049502"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.170"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.4331\/wjbc.v3.i4.73"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.12.016"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2015.12.021"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.13799"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.114"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1440-1681.12924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.12924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T02:38:05Z","timestamp":1695436685000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1440-1681.12924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,11]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/1440-1681.12924"],"URL":"https:\/\/doi.org\/10.1111\/1440-1681.12924","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"type":"print","value":"0305-1870"},{"type":"electronic","value":"1440-1681"}],"subject":[],"published":{"date-parts":[[2018,3,11]]}}}